The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

The layoffs at the gene therapy company are part of restructuring of Spark Therapeutics by its owner, Roche Group.

CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks ...

Javed Shaikh, Director of RWE & HEOR, Axtria, explains how harnessing next-generation sequencing and AI-powered analytics ...

The major workforce overhaul comes a month after parent company Roche deemed the cell and gene therapy firm a financial loss.